A Non-blinded Retrospective Biomarker add-on Study to FIGARO-DKD for Bioprofiling the Pharmacodynamic Response to Finerenone in FIGARO-DKD Subjects
Latest Information Update: 07 Nov 2023
At a glance
- Drugs Finerenone (Primary)
- Indications Diabetic nephropathies
- Focus Biomarker; Pharmacodynamics
- Acronyms FIGARO-BM
- Sponsors Bayer
- 02 Nov 2023 According to a Bayer media release, data from this study were presented at the American Society of Nephrology's (ASN) Kidney Week 2023.
- 05 Jan 2022 Status changed from recruiting to completed.
- 03 Sep 2021 Status changed from not yet recruiting to recruiting.